A5081673298- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Economic and Financial Impacts of Cancer
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Genetic factors in colorectal cancer
- Hepatitis B Virus Studies
- Gastric Cancer Management and Outcomes
- Genomics and Rare Diseases
- Transplantation: Methods and Outcomes
- Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
- MicroRNA in disease regulation
- Imbalanced Data Classification Techniques
- COVID-19 and healthcare impacts
- Global Cancer Incidence and Screening
- BRCA gene mutations in cancer
- Organ Transplantation Techniques and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Peptidase Inhibition and Analysis
- Ethics in Clinical Research
- Folate and B Vitamins Research
Cholangiocarcinoma Foundation
2017-2025
This report presents the American Society of Clinical Oncology's (ASCO's) evaluation adaptations in care delivery, research operations, and regulatory oversight made response to coronavirus pandemic recommendations for moving forward as recedes. ASCO organized its clinical around five goals ensure lessons learned from COVID-19 experience are used craft a more equitable, accessible, efficient system that protects patient safety, ensures scientific integrity, maintains data quality. The...
Historically, data from US death certificates, available through the CDC's WONDER database, have been used to highlight health disparities. The 5 year (2018-2022) underlying-cause-of-death were analyzed for different race/ethnicity groups. Gastrointestinal (GI) cancers of colon/rectum, pancreas, liver/bile duct, and stomach contributed more than a quarter cancer deaths in US, calling focused advocacy. Known disparities Black non-Hispanic Americans verified pancreas. However, mortality 'More...
Background: Liver transplantation (LT) provides the best long-term survival outcomes for patients with liver cancer. As a result, field of transplant oncology has grown greatly over past few decades, and many centers have expanded their criteria to allow increased access LT malignancies. Center-level guidelines practices in significantly vary across world, leading debate regarding course treatment this patient population. Methods: An international consensus conference was convened by...
Abstract Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates treatment these populations, focusing on use of adjuvant, liver-directed, targeted, investigational therapies. Methods multicenter collaboration included patients with ICC or ECC treated at 1 8 participating institutions. Retrospective data were collected risk factors, pathology,...
Researchers wanted to study whether the research drug zanidatamab could help people with a type of cancer called biliary tract cancer. In some people, cells make extra copies gene HER2 (also ERBB2). This is known as being HER2-amplified. Zanidatamab an antibody designed destroy that have higher-than-normal protein or levels. currently under and not yet approved for any diseases. Participants in this phase 2b clinical had tumors were HER2-amplified at advanced metastatic stage. also which...
PURPOSE Increased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes this population. However, cholangiocarcinoma (CCA), a paucity data exist on AYA To our knowledge, we present largest study date disease biology, treatment patterns, survival CCA. METHODS A multi-institutional cohort patients CCA diagnosed intrahepatic (ICC) or extrahepatic (ECC) was used analysis. Retrospective chart review conducted who were 50...
Biliary tract cancer (BTC) is a rare, lethal, heterogeneous group of cancers often diagnosed at an advanced stage. While gemcitabine plus cisplatin the standard care for first-line treatment locally or metastatic BTC, no globally accepted currently exists second-line BTC following chemotherapy. However, landscape evolving with approvals therapies targeting actionable mutations. This study aimed to characterize patterns and survival in patients BTC.
Abstract Purpose Numerous experimental and targeted therapies are under investigation for patients with cholangiocarcinoma (CCA). Objective health‐related quality of life (HRQoL) data receiving these limited. Methods Patients engaged in the Cholangiocarcinoma Foundation completed two validated HRQoL surveys: Functional Assessment Cancer Therapy (FACT)‐Hepatobiliary COmprehensive Score financial Toxicity (COST). Results Two hundred eight were included. Seventy‐five percent had intrahepatic...
e24164 Background: Biomarker testing has advanced precision medicine in cancer. However, not all eligible patients benefit from biomarker-driven therapies due to suboptimal rates. A working group of 20 patient advocacy groups representing solid/hematologic malignancies, three professional societies, and 18 pharmaceutical diagnostics companies identified confusion inconsistent terms as a possible contributing factor biomarker underutilization. The aimed address patients’ by identifying...
545 Background: Targeted therapy for actionable mutations in advanced cholangiocarcinoma (CCA) has revolutionized second and third-line treatment algorithms. Their application early stage disease is not defined. The incidence prognostic value of pts with resected known. Methods: Cholangiocarcinoma Foundation Ciitizen (a wholly owned subsidiary Invitae Corporation) collaboratively launched a registry platform that directly consents collects comprehensive medical records. Presently,...
Aim: To understand cholangiocarcinoma symptoms, diagnosis and treatment experience from the patient caregiver perspective, including cholangiocarcinoma's impact on daily life, quality of life (QoL) mental health. Methods: Patients caregivers participated in two online surveys (in partnership with Cholangiocarcinoma Foundation). Results: The survey data (n = 707) show a substantial QoL health, 34% patients reporting symptoms consistent moderately severe/severe depression. 60) that although...
277 Background: Patients (pts) with CCA typically present advanced disease and face a poor prognosis impaired quality of life (QoL). Despite improvements in therapies, the impact on pts’ daily lives has been rarely studied. This pt-focused survey explored diagnostic journey, including work status, QoL psychosocial impacts CCA. Methods: Pts were recruited partnership Cholangiocarcinoma Foundation from Aug 23 through Sept 20, 2019, categorized by AJCC stage. participated 30-min online to...
407 Background: Cholangiocarcinoma (CCA) is a rare and aggressive cancer, with most patients presenting at an advanced stage few treatment options. In the past decade, number of clinical trials available to CCA has increased significantly. Recent for FGFR2 IDH1 inhibitors showed significant improvement in patients’ overall survival progression-free led approval three new targeted therapies over last year half. Unfortunately, small percentage were eligible this treatment. As standard limited...
4084 Background: Treatment of advanced CCA has changed dramatically over the past five years with advent molecularly targeted therapy, now approved in 2nd line and beyond. However, real world utilization molecular profiling therapy is still unknown these data are critical to empower treatment decision-making. Methods: In 2019, Cholangiocarcinoma Foundation (CCF) Ciitizen (a wholly owned subsidiary Invitae Corporation) collaboratively launched a registry platform that directly consents...
240 Background: As seen in lung cancer, young patients with cancer can have different risk factors, presentation, and tumor genotype than older the same disease. The clinical molecular features of CCA yet to be well characterized. Methods: Retrospective chart review was performed on intrahepatic (ICC) or extrahepatic cholangiocarcinoma (ECC) across 5 institutions. Data demographics, treatments, pathology, overall survival (OS) were collected. Tumor genotyping results from MGH SNaPShot...
394 Background: While surgery is the only curative option for cholangiocarcinoma (CCA), it amenable in a minority of patients and has high recurrence rates. Numerous experimental targeted therapies are under investigation; however, objective health-related quality life (HRQoL) data receiving these currently not available. Methods: Pts engaged Cholangiocarcinoma Foundation completed two validated HRQoL surveys: Functional Assessment Cancer Therapy (FACT)-Hepatobiliary COmprehensive Score...
As a 12-year survivor of advanced-stage intrahepatic cholangiocarcinoma, I have experienced numerous surgeries, chemotherapy regimens, and adverse effects. After my disease recurred, looked to clinical trial as best chance survival, but insurance would not cover the unforeseen costs enrolling in one. Because bear those myself, made difficult decision enroll avoid putting family financial distress. failed control 2 years later, came point where quality life became more important than how long...